home All News open_in_new Full Article

Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatric Designation granted MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy HAIFA, Israel, April 03, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd, a […]


today 3 w. ago attach_file Other

attach_file Economics
attach_file Other
attach_file Other
attach_file Sport
attach_file Society
attach_file Society
attach_file Politics
attach_file Sport
attach_file Culture
attach_file Events
attach_file Other
attach_file Culture
attach_file Politics
attach_file Other
attach_file Sport
attach_file Sport
attach_file Other
attach_file Politics
attach_file Other
attach_file Other


ID: 3326248418
Add Watch Country

arrow_drop_down